The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Health-Related Quality of Life and Functional Outcomes from a Randomized-Withdrawal Study of Long-Term Lisdexamfetamine Dimesylate Treatment in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
Open accessAbstract
BACKGROUND: The stimulant prodrug lisdexamfetamine dimesylate (LDX) is an effective and generally well tolerated treatment for the symptoms of attention-deficit/hyperactivity disorder (ADHD). Positive impacts of LDX on health-related quality of life and functional impairment have previously been demonstrated in a 7-week, randomized, double-blind, placebo-controlled, phase III study in children and adolescents in Europe. Maintenance of these broad benefits, as well as symptomatic control, is a key goal of long-term management of ADHD. OBJECTIVE: Secondary objectives of this multinational study in children and adolescents with ADHD were to assess the long-term maintenance of effectiveness of LDX in improving health-related quality of life and reducing functional impairment, as gauged using the Child Health and Illness Profile-Child Edition: Parent Report Form (CHIP-CE: PRF) and the Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P), respectively. METHODS: Patients aged 6-17 years with diagnosed ADHD and a baseline ADHD Rating Scale IV total score of at least 28 were enrolled from the previous European study and from US sites. Patients who completed an open-label LDX treatment period of at least 26 weeks were randomized (1:1) to continue on their optimized dose of LDX or to switch to placebo for a 6-week, double-blind, withdrawal period. Parents completed CHIP-CE: PRF and WFIRS-P questionnaires at weeks 0, 8 and 26 of the open-label period and at weeks 0 and 6 of the randomized-withdrawal period, or at early termination. The endpoint of each period was defined as the last visit with valid data. Effect sizes were the difference (LDX minus placebo) in least-squares (LS)-mean change from baseline to endpoint divided by root-mean-square error. P values were nominal and not adjusted for multiple comparisons. RESULTS: The open-label and randomized full analysis sets comprised 262 and 153 (LDX n = 76; placebo n = 77) patients, respectively. Mean pretreatment CHIP-CE: PRF T-scores were more than one standard deviation below the normative mean in four of the five domains, and there was significant improvement across all domains from baseline to endpoint of the open-label period. In the randomized-withdrawal period, LS-mean CHIP-CE: PRF T-scores deteriorated in all domains in the placebo group, but not in the LDX group. Compared with placebo, the effect of LDX was significant in the Risk Avoidance (effect size 0.829; p < 0.001), Achievement (0.696; p < 0.001) and Satisfaction (0.636; p < 0.001) domains. Mean pretreatment WFIRS-P scores were lowest in the Family domain and the Learning and School domain. WFIRS-P total score and scores in all domains improved significantly from baseline to endpoint of the open-label period. In the randomized-withdrawal period, LS-mean scores deteriorated in the placebo group but not in the LDX group. Compared with placebo, the effect of LDX was significant in the Family, Learning and School, and Risky Activities domains and in total (effect size 0.908; p < 0.001). CONCLUSIONS: Using parent-rated instruments, long-term maintenance of the beneficial effect of LDX in multiple domains of health-related quality of life and functional impairment was demonstrated by comparison of treatment continuation and withdrawal under randomized, double-blind, placebo-controlled conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 CHIP-CE: PRF T-scores during the open-label period (n = 262). a Mean T-scores at open-label baseline and histogram showing mean change from open-label baseline to endpoint for CHIP-CE: PRF domains and subdomains. Error bars show 95 % CIs. Positive changes indicate improved HRQoL. ***p < 0.001, **p < 0.01, change at endpoint versus baseline (two-sided t test). P values are nominal and were not adjusted for multiple comparisons. b Mean CHIP-CE: PRF domain T-scores at baseline (BL), endpoint (EP), visit 6 (V6 8 weeks) and visit 3R (V3R ≥26 weeks) of the open-label period. Error bars show 95 % confidence intervals. These data were not subjected to statistical testing. Numbers of observations (n) are shown for each data point. A T-score of 43 or below indicates poor HRQoL in a domain or subdomain; a T-score of 57 or above indicates excellent HRQoL [20]. The horizontal axis is positioned at the normative mean (T-score of 50). BL baseline, CHIP-CE: PRF Child Health and Illness Profile-Child Edition: Parent Report Form, CI confidence interval, EP endpoint, HRQoL health-related quality of life, R revised, SD standard deviation, V visit](https://figures.cochat.ai/paper-figures/5eb3b95e01f94125b28ba8822b4a4651/health-related-quality-of-life-and-functional-outcomes-from-a-randomized-figure-2.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“one study found that medication-related improvement of HRQOL persisted following medication withdrawal, even when symptom severity increased 236 , indicating that any potential causeeffect relationships between medication use, symptom and functional impairment reduction and HRQOL require further investigation.”
From Attention-deficit/hyperactivity disorder (2015) · cites this paper as [236]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Cohen, J. (1992) · Psychological Bulletin · doi:10.1037//0033-2909.112.1.155 · Cited by 8,771
The quality of life of children with attention deficit/hyperactivity disorder: a systematic review
Danckaerts, M., Sonuga-Barke, E. J. S., Banaschewski, T., Buitelaar, J., Döpfner, M., Hollis, C., Santosh, P., Rothenberger, A., Sergeant, J., Steinhausen, H.-C., et al. (2010) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0046-3 · Cited by 516
Self-citationBiederman, J., Krishnan, S., Zhang, Y., McGough, J. J., & Findling, R. L. (2007) · Clinical Therapeutics · doi:10.1016/s0149-2918(07)80083-x · Cited by 404
MICHELSON, D., BUITELAAR, J. K., DANCKAERTS, M., GILLBERG, C., SPENCER, T. J., ZUDDAS, A., FARIES, D. E., ZHANG, S., & BIEDERMAN, J. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000125089.35109.81 · Cited by 307
Self-citationThe Child Report Form of the CHIP–Child Edition: Reliability and Validity
Riley, A. W., Forrest, C. B., Rebok, G. W., Starfield, B., Green, B. F., Robertson, J. A., & Friello, P. (2004) · Medical Care · doi:10.1097/01.mlr.0000114910.46921.73 · Cited by 243
Adler, L. A., Goodman, D. W., Kollins, S. H., Weisler, R. H., Krishnan, S., Zhang, Y., & Biederman, J. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0903 · Cited by 218
Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine
Pennick (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s9749 · Cited by 170 · cited 1×
“Lisdexamfetamine dimesylate (LDX), the first long-acting stimulant prodrug, undergoes rate-limiting enzymatic bioconversion to d-amfetamine in the bloodstream [1] and provides a daily duration of efficacy of at least 13 h post-dose in children and 14 h in adults, as determined in laboratory school and simulated workpl…”
BackgroundCoghill, D., Danckaerts, M., Sonuga-Barke, E. J. S., Sergeant, J. A., & the ADHD European Guidelines Group (2009) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2009.02008.x · Cited by 163
Self-citation
Research works printed but not linked: 1
- Riley AW, Robertson JA, Forrest CB, Green BF, Rebok GW, Starfield B. Technical manual for the Child Health and Illness Profile-Child Edition (CHIP-CE) Parent and Child Report Forms (Version 1.0). Baltimore: Johns Hopkins University; 2001.
Cited by
Attention-deficit/hyperactivity disorder
Faraone, S. V., Asherson, P., Banaschewski, T., Biederman, J., Buitelaar, J. K., Ramos-Quiroga, J. A., Rohde, L. A., Sonuga-Barke, E. J. S., Tannock, R., & Franke, B. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.20 · Cited by 1,479
Self-citationEvidence-based pharmacological treatment options for ADHD in children and adolescents
Mechler, K., Banaschewski, T., Hohmann, S., & Häge, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107940 · Cited by 293
Self-citationCoghill, D., Banaschewski, T., Soutullo, C. A., Cottingham, M. G., & Zuddas, A. (2017) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-017-0986-y · Cited by 150
Self-citationWeiss, M. D., McBride, N. M., Craig, S. G., & Jensen, P. S. (2018) · Evidence-Based Mental Health · doi:10.1136/ebmental-2018-300025 · Cited by 120
Wilens, T. E., Robertson, B., Sikirica, V., Harper, L., Young, J. L., Bloomfield, R., Lyne, A., Rynkowski, G., & Cutler, A. J. (2015) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2015.08.016 · Cited by 75
Metadata
- Authors
- Banaschewski, T., Johnson, M., Lecendreux, M., Zuddas, A., Adeyi, B., Hodgkins, P., Squires, L. A., & Coghill, D. R.
- Affiliations
- Heidelberg University (DE)
- Drottning Silvias barn- och ungdomssjukhus (SE)
- Hôpital Robert-Debré (FR)
- University of Cagliari (IT)
- Takeda (United States) (US)
- University of Dundee (GB)
- Corresponding author
- Banaschewski, Tobias
- ORCID
- Venue
- CNS Drugs
- Published
- 2014-08-20
- Volume
- 28
- Issue
- 12
- Pages
- 1191-1203
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- PMC
- PMC4246127
- OpenAlex
- W2045793565
- Cited by
- 41
- References
- 31
- Citations by year
- 2024: 3 · 2023: 2 · 2022: 4 · 2021: 3 · 2020: 6 · 2019: 1 · 2018: 7 · 2017: 6 · 2016: 4 · 2015: 5
- FWCI
- 3.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- CNS Drugs (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Vertex Pharmaceuticals
- University of Oxford
- Vifor Pharma
- H. Lundbeck A/S
- Cilag
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- lisdexamfetamine dimesylate, attention deficit hyperactivity disorder, children and adolescents, health-related quality of life, functional disability, Weiss Functional Impairment Rating Scale, parent-reported outcomes, ADHD symptoms, treatment efficacy and tolerability
- MeSH terms
- Lisdexamfetamine Dimesylate, Adolescent, Attention Deficit Disorder with Hyperactivity, Child, Dextroamphetamine, Double-Blind Method, Europe, Female, Humans, Male, Psychiatric Status Rating Scales, Psychotropic Drugs, Quality of Life, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Health-Related Quality of Life and Functional Outcomes from a Randomized-Withdrawal Study of Long-Term Lisdexamfetamine Dimesylate Treatment in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. https://app.cochat.ai/papers/10.1007/s40263-014-0193-z
- The paper
- Banaschewski, T., Johnson, M., Lecendreux, M., Zuddas, A., Adeyi, B., Hodgkins, P., Squires, L. A., & Coghill, D. R. (2014). Health-Related Quality of Life and Functional Outcomes from a Randomized-Withdrawal Study of Long-Term Lisdexamfetamine Dimesylate Treatment in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. CNS Drugs. https://doi.org/10.1007/s40263-014-0193-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.